Atara Biotherapeutics Stock News

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon sold 8,402 shares of the stock in a transaction on Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total transaction of $143,842.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon sold 8,402 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total transaction of $143,842.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Shares []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) SVP Amar Murugan sold 2,124 shares of the stock in a transaction dated Tuesday, November 16th. The shares were sold at an average price of $17.12, for a total value of $36,362.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this []

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 3,655 shares of the businesss stock in a transaction that occurred on Tuesday, November 16th. The stock was sold at an average price of $17.12, for a total transaction of $62,573.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC []

In the last trading session, 1.01 million Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares changed hands as the companys beta touched 1.93. With the companys per share price at $17.37 changed hands at $0.3 or 1.76% during last session, the market valuation stood at $1.53B. ATRAs last price was a discount, traded about -62.35% off its 52-week Atara Biotherapeutics Inc. (NASDAQ: ATRA) Is Expected To Soar To Higher Prices In The Months To Come. Read More »

Related Stocks: TGTX , ISEE , RNW , ATRA , IMRA , MCRB , ORGN , CNP , EXTR , CSIQ ,

Related Stocks: PFE , TMO , TDOC , BMRN , JNJ , ALLO , VRTX , ATRA , ZNTL , TCRR , ACCD , JAZZ ,

Zacks Investment Research downgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a buy rating to a hold rating in a research note released on Thursday morning, Zacks.com reports. According to Zacks, Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript

The consensus price target hints at a 48.3% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 2.17% and 1.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to

SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformati